IL265028A - - Google Patents
Info
- Publication number
- IL265028A IL265028A IL26502819A IL26502819A IL265028A IL 265028 A IL265028 A IL 265028A IL 26502819 A IL26502819 A IL 26502819A IL 26502819 A IL26502819 A IL 26502819A IL 265028 A IL265028 A IL 265028A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395618P | 2016-09-16 | 2016-09-16 | |
| PCT/US2017/051780 WO2018053267A1 (en) | 2016-09-16 | 2017-09-15 | Inhibitors of the menin-mll interaction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL265028A true IL265028A (https=) | 2019-04-30 |
| IL265028B IL265028B (en) | 2022-09-01 |
Family
ID=59966892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295972A IL295972A (en) | 2016-09-16 | 2017-09-15 | Inhibitors of the menin-mll interaction |
| IL265028A IL265028B (en) | 2016-09-16 | 2017-09-15 | Inhibitors of the menin-mil interaction |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295972A IL295972A (en) | 2016-09-16 | 2017-09-15 | Inhibitors of the menin-mll interaction |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10899758B2 (https=) |
| EP (2) | EP4230627A3 (https=) |
| JP (3) | JP2019529421A (https=) |
| KR (1) | KR102536029B1 (https=) |
| CN (3) | CN110325533B (https=) |
| AR (1) | AR109658A1 (https=) |
| AU (1) | AU2017326006B2 (https=) |
| CA (1) | CA3036987A1 (https=) |
| DK (1) | DK3512850T3 (https=) |
| ES (1) | ES2948949T3 (https=) |
| FI (1) | FI3512850T3 (https=) |
| IL (2) | IL295972A (https=) |
| MX (2) | MX2019003091A (https=) |
| PL (1) | PL3512850T3 (https=) |
| TW (1) | TWI757340B (https=) |
| WO (1) | WO2018053267A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| HK1246593A1 (zh) | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| US10869868B2 (en) | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| EP3512857B1 (en) | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro bicyclic inhibitors of menin-mll interaction |
| AU2017326006B2 (en) * | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| CN110248946B (zh) | 2016-12-15 | 2023-05-23 | 詹森药业有限公司 | Menin-MLL相互作用的氮杂环庚烷抑制剂 |
| WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| MX2019011412A (es) | 2017-03-31 | 2020-02-07 | Univ Michigan Regents | Piperidinas como inhibidores de menina covalentes. |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| EP3684361A4 (en) | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| JP7307729B2 (ja) | 2017-12-20 | 2023-07-12 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤 |
| US11447484B2 (en) * | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| KR102779601B1 (ko) * | 2018-08-27 | 2025-03-12 | 스미토모 파마 가부시키가이샤 | 광학 활성인 아자비시클로환 유도체 |
| CA3106385A1 (en) * | 2018-09-13 | 2020-03-19 | Kissei Pharmaceutical Co., Ltd. | Imidazopyridinone compound |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| AU2019395201A1 (en) | 2018-12-06 | 2021-05-20 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
| DK4013756T3 (da) * | 2019-09-20 | 2024-05-27 | Novartis Ag | MLL1-inhibitorer og anticancermidler |
| JP7618567B2 (ja) * | 2019-09-27 | 2025-01-21 | 住友ファーマ株式会社 | 架橋型光学活性２級アミン誘導体 |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| CN115210229A (zh) | 2020-01-03 | 2022-10-18 | 博格有限责任公司 | 多环酰胺作为治疗癌症的ube2k调节剂 |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| TW202200589A (zh) | 2020-05-28 | 2022-01-01 | 瑞士商諾華公司 | Ｍｌｌ１抑制劑及抗癌劑 |
| EP4263535A1 (en) | 2020-12-17 | 2023-10-25 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| CA3215379A1 (en) | 2021-05-08 | 2022-11-17 | Olivier Alexis Georges Querolle | Substituted spiro derivatives |
| US20240417405A1 (en) | 2021-05-08 | 2024-12-19 | Janssen Pharmaceutica Nv | Substituted Spiro Derivatives |
| IL308476A (en) | 2021-05-14 | 2024-01-01 | Syndax Pharmaceuticals Inc | Inhibitors of the menin-mil interaction |
| IL308862A (en) | 2021-06-01 | 2024-01-01 | Janssen Pharmaceutica Nv | Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories |
| JP2024521902A (ja) | 2021-06-03 | 2024-06-04 | ヤンセン ファーマシューティカ エヌ．ベー． | スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン |
| WO2022262796A1 (en) | 2021-06-17 | 2022-12-22 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| CN116903609A (zh) * | 2021-11-05 | 2023-10-20 | 上海优理惠生医药有限公司 | 一种化合物、包含其的药物组合物及其应用 |
| US20250000799A1 (en) * | 2021-11-11 | 2025-01-02 | V-Ensure Pharma Technologies Private Limited | Reconstitutable, Single Use Antidiabetic Compositions |
| US20250197392A1 (en) * | 2022-04-08 | 2025-06-19 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| JP2025541695A (ja) * | 2022-11-30 | 2025-12-23 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換１－フェニル－３，４－ジヒドロピリド［３，４－ｄ］ピリミジン－２－オン誘導体 |
| CN120359221A (zh) * | 2022-11-30 | 2025-07-22 | 詹森药业有限公司 | 环丁基取代的双环化合物 |
| WO2024114666A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
| EP4626426A1 (en) * | 2022-11-30 | 2025-10-08 | JANSSEN Pharmaceutica NV | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
| AR132185A1 (es) * | 2023-03-24 | 2025-06-04 | Acerta Pharma Bv | COMPUESTOS DE 1-H-PIRROLO[2,3-c]PIRIDINA |
| CN121969626A (zh) * | 2023-09-27 | 2026-05-01 | 苏州必扬医药科技有限公司 | 一种Menin-MLL相互作用抑制剂及其制备方法和应用 |
| WO2025119184A1 (zh) * | 2023-12-04 | 2025-06-12 | 首药控股(北京)股份有限公司 | 取代的多环化合物 |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
| WO2026062248A1 (en) * | 2024-09-20 | 2026-03-26 | Acerta Pharma B.V. | Solid-state forms of ((s)-2-(3-(1-(5,5-dimethylpyrrolidine-2-carbonyl)piperidine-4-carbonyl)-2-methyl-1h-pyrrolo[2,3-c]-pyridin-1-yl)-5-fluoro-n,n-diisopropylbenzamide salts |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2253930T3 (es) | 1998-09-18 | 2006-06-01 | ABBOTT GMBH & CO. KG | 4-aminopirrolopirimidinas como inhibidores de quinasa. |
| WO2006114180A1 (de) | 2005-04-25 | 2006-11-02 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
| WO2010066629A2 (en) | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
| GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| TWI500617B (zh) * | 2010-05-31 | 2015-09-21 | Ono Pharmaceutical Co | Purine ketone derivatives |
| MX2014004086A (es) | 2011-10-03 | 2014-09-22 | Univ North Carolina | Compuestos de pirrolopirimidina para el tratamiento del cancer. |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| JP6327713B2 (ja) * | 2012-07-27 | 2018-05-23 | 国立研究開発法人理化学研究所 | 急性骨髄性白血病の治療又は再発抑制剤 |
| EA201590855A1 (ru) * | 2012-11-15 | 2015-11-30 | Фармасайкликс, Инк. | Соединения пирролопиримидина как ингибиторы киназ |
| US20160113893A1 (en) * | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| CA2922058A1 (en) * | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| JP6793401B2 (ja) | 2015-03-11 | 2020-12-02 | 国立研究開発法人理化学研究所 | 難治性白血病治療薬 |
| AU2017326006B2 (en) * | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
-
2017
- 2017-09-15 AU AU2017326006A patent/AU2017326006B2/en active Active
- 2017-09-15 CN CN201780063763.2A patent/CN110325533B/zh active Active
- 2017-09-15 FI FIEP17772585.0T patent/FI3512850T3/fi active
- 2017-09-15 KR KR1020197010730A patent/KR102536029B1/ko active Active
- 2017-09-15 CN CN202511525384.3A patent/CN121735946A/zh active Pending
- 2017-09-15 TW TW106131767A patent/TWI757340B/zh active
- 2017-09-15 CA CA3036987A patent/CA3036987A1/en active Pending
- 2017-09-15 US US16/333,852 patent/US10899758B2/en active Active
- 2017-09-15 MX MX2019003091A patent/MX2019003091A/es unknown
- 2017-09-15 JP JP2019514787A patent/JP2019529421A/ja not_active Withdrawn
- 2017-09-15 EP EP23167055.5A patent/EP4230627A3/en active Pending
- 2017-09-15 EP EP17772585.0A patent/EP3512850B1/en active Active
- 2017-09-15 IL IL295972A patent/IL295972A/en unknown
- 2017-09-15 PL PL17772585.0T patent/PL3512850T3/pl unknown
- 2017-09-15 IL IL265028A patent/IL265028B/en unknown
- 2017-09-15 ES ES17772585T patent/ES2948949T3/es active Active
- 2017-09-15 CN CN202410398451.9A patent/CN118359610A/zh active Pending
- 2017-09-15 AR ARP170102556A patent/AR109658A1/es active IP Right Grant
- 2017-09-15 DK DK17772585.0T patent/DK3512850T3/da active
- 2017-09-15 WO PCT/US2017/051780 patent/WO2018053267A1/en not_active Ceased
-
2019
- 2019-03-15 MX MX2022013841A patent/MX2022013841A/es unknown
-
2020
- 2020-08-11 US US16/990,657 patent/US11739085B2/en active Active
-
2022
- 2022-10-06 JP JP2022161777A patent/JP2022189853A/ja active Pending
-
2023
- 2023-05-18 US US18/320,111 patent/US20240124447A1/en not_active Abandoned
-
2024
- 2024-11-08 JP JP2024195965A patent/JP2025022910A/ja active Pending